Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Malaysian Approval of FLEXISEQ™ and Distribution Agreement

Abstract:
Pro Bono Bio™ is pleased to announce that its innovative product FLEXISEQ, a new nanotechnology based treatment for osteoarthritis, has received approval for sale in Malaysia. This follows the successful launch of FLEXISEQ in Europe earlier this year.

Malaysian Approval of FLEXISEQ™ and Distribution Agreement

Malaysia | Posted on June 18th, 2012

Pro Bono Bio is also pleased to announce that they have signed an agreement to distribute FLEXISEQ in Malaysia and the product will be available via local distribution company, Farmasia Sdn. Bhd. from early July 2012. Its first introduction to the local market is at the 42nd Annual Scientific Meeting of the Malaysian Orthopaedic Association in Kuantan, Malaysia held between the 14th and 17th of June 2012.

Michael Earl, COO of Pro Bono Bio, said "Pro Bono Bio is an ambitious new international pharmaceutical company which expects to make a real difference for patients, doctors and payors alike by developing truly innovative products to address areas of real need. It is a pleasure to launch our product FLEXISEQ here in Malaysia following our success in Europe. We look forward to introducing further innovative products this year and are also considering where to site our regional headquarters and manufacturing facilities to support our products in South East Asia."

Zohrah Razak Al Aidruss of Farmasia said "It is wonderful to have reached an agreement to introduce such an innovative product into Malaysia. The unique mode of action and lack of the side effects associated with various existing drug products, makes this a very welcome addition to the solutions available for physicians managing Osteoarthritis (OA). OA effects millions of patients in Malaysia, and both global and local trials have proved the effectiveness of FLEXISEQ at relieving joint pain associated with OA."

####

About Pro Bono Bio
Pro Bono Bio is a new international healthcare company based on the experience in pharmaceutical product development, commercialisation and finance of Celtic Pharma Holdings in the UK, international capital, along with investment and support from RUSNANO in Russia. Pro Bono Bio has ambitious growth targets that will allow it to support a unique humanitarian mission.

Pro Bono Bio launched its first medical device, FLEXISEQ, a new nanotechnology based pain treatment for osteoarthritis, in Europe in the first half of 2012. The Company also plans to launch two further new products for the treatment of inflammatory skin disorders in the second half of 2012. These new products are based on Pro Bono Bio's innovative Sequessome Technology™.

Pro Bono Bio is also developing new products to treat haemophilia as well as novel antibiotics for the treatment of serious infections such as C. difficile, MRSA, Pneumonia and Tuberculosis.

About FLEXISEQ

FLEXISEQ is the safe way to reduce joint pain associated with osteoarthritis. FLEXISEQ benefits from a Class 2A Medical Device certification in Europe. It is a topically applied gel which uses the unique Sequessome Technology to pass through the skin and apply a biolubricant layer inside the effected joint and along the cartilage. This improves the mobility in the joint and reduces the pain.

www.flexiseq.com

For more information, please click here

Contacts:
For further information please contact:
Zohrah Ab Razak Al-Aidruss


To order in Malaysia please contact:
Farmasia Sdn. Bhd.
+603-62032334

For London based press please contact:
Citigate Dewe Rogerson
David Dible / Nina Enegren
Tel: +44(0)207-282-1050

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

GS7 Graphene Sensor maybe Solution in Fight Against Cancer January 25th, 2015

Toyocolor to Launch New Carbon Nanotube Materials at nano tech 2015 January 24th, 2015

NANOPOSTER 2015 - 5th Virtual Nanotechnology Conference - call for abstracts January 24th, 2015

Nanosensor Used for Simultaneous Determination of Effective Tea Components January 24th, 2015

Govt.-Legislation/Regulation/Funding/Policy

The latest fashion: Graphene edges can be tailor-made: Rice University theory shows it should be possible to tune material's properties January 24th, 2015

Scientists 'bend' elastic waves with new metamaterials that could have commercial applications: Materials could benefit imaging and military enhancements such as elastic cloaking January 23rd, 2015

Harper Government Supports Research Innovation in Western Canada January 22nd, 2015

EnvisioNano: An image contest hosted by the National Nanotechnology Initiative (NNI) January 22nd, 2015

Nanomedicine

Teijin to Participate in Nano Tech 2015 January 22nd, 2015

2nd International Conference on Infectious Diseases & Nanomedicine (December 15-18, 2015, Kathmandu, NEPAL) January 22nd, 2015

Anti-microbial coatings with a long-term effect for surfaces – presentation at nano tech 2015 in Japan January 21st, 2015

A spoonful of sugar in silver nanoparticles to regulate their toxicity January 21st, 2015

Announcements

GS7 Graphene Sensor maybe Solution in Fight Against Cancer January 25th, 2015

Toyocolor to Launch New Carbon Nanotube Materials at nano tech 2015 January 24th, 2015

NANOPOSTER 2015 - 5th Virtual Nanotechnology Conference - call for abstracts January 24th, 2015

Nanosensor Used for Simultaneous Determination of Effective Tea Components January 24th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE